References
- Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against covid-19 omicron variant. N Engl J Med. 2022;386(10):995–998. doi:10.1056/NEJMc2119407.
- Committee for Medicinal Products for Human Use (CHMP) - EMA. Assessment report: eli lilly and company limited use of bamlanivimab and etesevimab for the treatment of COVID-19. 2021.
- Wolf J, Abzug MJ, Anosike BI, et al. Updated guidance on use and prioritization of monoclonal antibody therapy for treatment of COVID-19 in adolescents. J Pediatric Infect Dis Soc. 2022;11(5):177–185. doi:10.1093/jpids/piab124.
- Heo YA. Sotrovimab: first approval. Drugs. 2022;82(4):477–484. doi:10.1007/s40265-022-01690-7.
- Shrestha LB, Foster C, Rawlinson W, et al. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol. 2022;32(5):e2381.
- Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–1950. doi:10.1056/NEJMoa2107934.
- Romani L, Calò Carducci FI, Chiurchiù S, et al. Safety of monoclonal antibodies in children affected by SARS-CoV-2 infection. Children (Basel). 2022;9(3):369. doi:10.3390/children9030369.
- Pruccoli G, Bertorello N, Funiciello E, et al. A single-center experience in treating young children at high risk For severe COVID-19 With sotrovimab. Pediatr Infect Dis J. 2022;41(8):e341–e342. doi:10.1097/INF.0000000000003552.
- Di Chiara C, Mengato D, De Pieri M, et al. Early use of sotrovimab in children: a case report of an 11-Year-Old kidney transplant recipient infected with SARS-CoV-2. Children (Basel). 2022;9(4):451. doi:10.3390/children9040451.
- Lanari M, Venturini E, Pierantoni L, et al. Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an italian inter-society consensus statement. Ital J Pediatr. 2022;48(1):7. doi:10.1186/s13052-021-01187-1.
- Weber SC, Danne F, Kieslich M, et al. Sotrovimab in pediatric cardiac transplant recipients with SARS-CoV2 infection. J Heart Lung Transplant. 2022;41(8):1124–1126. doi:10.1016/j.healun.2022.05.003.
- Rau C, Auer-Hackenberg L, Deubzer HE, et al. Treatment of infants and children With SARS-CoV-2 monoclonal antibodies: a european case series. Pediatr Infect Dis J. 2023;42(2):125–129. doi:10.1097/INF.0000000000003773.
- Blind JE, Sapko M, Killough A, et al. Implementation and patient outcomes of a pediatric COVID-19 monoclonal antibody program. J Pediatric Infect Dis Soc. 2022;11(12):565–574. doi:10.1093/jpids/piac107.
- Zaqout A, Almaslamani MA, Chemaitelly H, et al. Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar. Int J Infect Dis. 2022;124:96–103. doi:10.1016/j.ijid.2022.09.023.
- Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 omicron sublineages. Nature. 2022;604(7906):553–556. doi:10.1038/s41586-022-04594-4.
- Food and Drug Administration. FDA updates sotrovimab emergency use authorization. 2022.
- Martin-Blondel G, Marcelin AG, Soulié C, et al. Sotrovimab to prevent severe COVID-19 in high-risk patients infected with omicron BA.2. J Infect. 2022;85(4):e104–e108.
- Węcławek-Tompol J, Zakrzewska Z, Gryniewicz-Kwiatkowska O, et al. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a polish national study. J Hematol Oncol. 2022;15(1):71. doi:10.1186/s13045-022-01279-3.
- Gupta A, Gonzalez-Rojas Y, Juarez E, et al. COMET-ICE investigators. Effect of sotrovimab on hospitalization or death Among high-risk patients With mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1236–1246.